Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

Novo Nordisk challenges Eli Lilly with data claiming superiority in oral obesity market

Novo Nordisk (NYSE:NVO) has intensified its rivalry with Eli Lilly (NYSE:LLY), releasing a provocative cross-trial analysis that claims its experimental Wegovy pill is both more effective and better tolerated than Lilly’s recently approved obesity tablet, Foundayo.

Leia mais: Novo Nordisk challenges Eli Lilly with data claiming superiority in oral obesity market